Biomass
$1.70
+6%
Broad Spectrum Distillate
$3,000.00
+3%
CBD Isolate
$1,100.00
+0%
CBG Isolate
$6,000.00
-7%
Water Soluble CBD Isolate
$2,300.00
+5%
Water Soluble CBD Broad Spectrum
$2,800.00
+2%
Back to news
14. May 2020
Market Watch News North America Pet & Animal Pharmaceutical

KND Labs Achieves Active Pharmaceutical Certification for CBD Ingredients

KND Labs, a leading manufacturer of hemp-derived ingredients, has received Active Pharmaceutical Ingredients (API) certification for its products, recognising the company as a certified manufacturer of CBD for pharmaceutical applications.

The announcement follows KND’s recent National Animal Supplement Council (NASC) certification, the Colorado-based manufacturer is one of the only companies in the world with both certifications. Additionally, KND recently submitted their UK Novel Foods ingredient application for review by the European Union.

Earlier this month, the DEA announced the de-scheduling of GW Pharmaceuticals’ Epidiolex, which has marijuana-derived CBD. Although KND ingredients are hemp-derived, which has long been considered a de-scheduled substance, it is a significant move towards CBD being widely recognised for pharmaceutical use.

We are thrilled to receive our API certification and the ability to propel CBD into the pharmaceutical space,” said Nich Wilson, president of KND. “With the DEA’s recent announcement they have de-scheduled CBD for prescription purposes, this is a historic time for our industry, and we are excited to be leading the way.

KND prides itself on its industry-leading methods to formulate heavily certified products, including its pure, plant-based CBD ingredients and customizable blends, allowing the pharmaceutical industry to gain confidence in CBD ingredients. KND’s’ formulations adhere to the highest-quality standards for manufacturing and testing to achieve the safest product available on the market. Currently, KND produces 1.2 billion doses per month, with the ability to increase capacity with new partners.

KND underwent a rigorous review of all manufacturing methods and processes by an independent third-party auditor to ensure the products have the highest-quality ingredients possible to provide reliability and consistency for finished goods to be used within pharmaceuticals.

Our team is proud to be at the forefront of certification, compliance and purity in our manufacturing process,” said Haakon Currie, compliance manager at KND. “It has always been our goal to distribute high-quality, plant-based CBD ingredients around the world.

In addition to being API and NASC certified, KND is cGMP 111 and 117 certified, ISO 9001:2015 certified and EFfCI (cosmetic euGMP) certified, as well as Kosher certified.

KND Labs continues to be fully operational during the COVID-19 pandemic, as CBD sales have increased, and KND continues to acquire clients in the pharmaceutical and pet industries resulting from new certifications. Despite the current period of economic uncertainty, demand from suppliers for high-quality cannabinoids continues to increase.

In its two state-of-the-art facilities in Lakewood, Colorado, and Arvada, Colorado, KND is focused on extracting quality, finished bulk ingredients for brands and manufacturers. KND is able to control the manufacturing process of its hemp-derived ingredients by extracting specific cannabinoid profiles to produce CBD, CBG and the isolation of other hemp-derived cannabinoids in a variety of forms including powdered isolate, distillate oils and liquid or powder water-soluble products.

Source | KND Labs